Table 1 Characteristics of included studies
From: Efficacy of convalescent plasma for the treatment of severe influenza
NO. | Author | Journal, years | Study design | Multi-center | Population | Dose | Treatment (n) | Control (n) | Outcomes |
|---|---|---|---|---|---|---|---|---|---|
1 | Hung, et al. [18] | CHEST, 2013 | RCT, H-IVIG vs. normal IV immunoglobulin (IVIG) | Yes | Patients with severe H1N1 infection | 0.4 g/kg | 17 | 17 | H-IVIG was associated with a lower viral load and reduced mortality |
2 | Group IFIPS [21] | The Journal of Infectious Diseases, 2016 | RCT, H-IVIG vs. placebo | Yes | Patients with influenza A or B | 0.25 g/kg | 16 | 15 | H-IVIG administration significantly increases HAI titer levels among patients with influenza |
3 | Davey Jr., et al. [17] | Lancet Respir Med, 2019 | RCT, H-IVIG vs. placebo | Yes | Patients with influenza A or B infection | 0.25 g/kg | 156 | 152 | H-IVIG was not superior to placebo for adults hospitalized with influenza infection |
4 | Beigel et al. [22] | Lancet Respir Med, 2017 | RCT, immune plasma vs. standard care | Yes | Patients with severe influenza A or B | HAI titers ≥ 1:80 | 42 | 45 | Immune plasma provided support for a possible benefit of severe influenza |
5 | Beigel et al. [16] | Lancet Respir Med, 2019 | RCT, high-titer anti-influenza plasma (≥ 1:80) vs. low-titer (≤ 1:10) | Yes | Patients with influenza A | HAI titers ≥ 1:80 | 91 | 47 | High-titer anti-influenza plasma conferred no significant benefit over non-immune plasma |